Press release
Investigation announced for Long-Term Investors in shares of PepGen Inc. (NASDAQ: PEPG) over potential Wrongdoing
An investigation on behalf of current long term investors in PepGen Inc. (NASDAQ: PEPG) shares.
Investors who are current long term investors in PepGen Inc. (NASDAQ: PEPG) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: PEPG stocks follows a lawsuit filed against PepGen Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: PEPG stocks, concerns whether certain PepGen Inc. directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the Eastern District of New York the plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that PGN-EDO51 was less effective and safe than Defendants had led investors to believe, that the CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration ("FDA") approval, that as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51's clinical, regulatory, and commercial prospects were overstated, and that as a result, Defendants' public statements were materially false and misleading at all relevant times.
Those who purchased shares of PepGen Inc. (NASDAQ: PEPG) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in shares of PepGen Inc. (NASDAQ: PEPG) over potential Wrongdoing here
News-ID: 4161282 • Views: …
More Releases from Shareholders Foundation, Inc.
First Solar, Inc. (NASDAQ: FSLR) Investor Alert: Deadline in Lawsuit on August 2 …
A deadline is coming up on August 24, 2026 in the lawsuit filed for certain investors of First Solar, Inc. (NASDAQ: FSLR) over alleged securities laws violations by First Solar, Inc.
Investors who purchased shares of First Solar, Inc. (NASDAQ: FSLR) have certain options and there are strict and short deadlines running. Deadline: August 24, 2026. First Solar, Inc. (NASDAQ: FSLR) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or…
Verra Mobility Corporation (NASDAQ: VRRM) Long Term Investor Alert: Investigatio …
An investigation on behalf of current long-term investors in shares of Verra Mobility Corporation (NASDAQ: VRRM) concerning potential breaches of fiduciary duties by certain directors and officers of Verra Mobility Corporation (NASDAQ: VRRM was announced.
Investors who are current long term investors in Verra Mobility Corporation (NASDAQ: VRRM) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law…
Hub Group, Inc. (NASDAQ: HUBG) Investor Alert: Deadline in Lawsuit on August 28, …
A deadline is coming up on August 28, 2026 in the lawsuit filed for certain investors of Hub Group, Inc. (NASDAQ: HUBG) over alleged securities laws violations by Hub Group, Inc.
Investors who purchased shares of Hub Group, Inc. (NASDAQ: HUBG) have certain options and there are strict and short deadlines running. Deadline: August 28, 2026. Hub Group, Inc. (NASDAQ: HUBG) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or…
Planet Fitness, Inc. (NYSE: PLNT) Investor Alert: Deadline in Lawsuit on Septemb …
A deadline is coming up on September 14, 2026 in the lawsuit filed for certain investors of Planet Fitness, Inc. (NYSE: PLNT) over alleged securities laws violations by Planet Fitness, Inc.
Investors who purchased shares of Planet Fitness, Inc. (NYSE: PLNT) have certain options and there are strict and short deadlines running. Deadline: September 14, 2026. Planet Fitness, Inc. (NYSE: PLNT) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call…
More Releases for PepGen
Myotonic Dystrophy Pipeline 2026: FDA Approvals and Clinical Trials Landscape wi …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Myotonic Dystrophy pipeline constitutes 20+ key companies continuously working towards developing 22+ Myotonic Dystrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Myotonic Dystrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
Investors who lost money with shares of PepGen Inc. (NASDAQ: PEPG) should contac …
An investor, who purchased shares of PepGen Inc. (NASDAQ: PEPG), filed a lawsuit over alleged violations of Federal Securities Laws by PepGen Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of PepGen Inc. (NASDAQ: PEPG) have certain options and for certain investors are short and strict deadlines running. Deadline: August 8, 2025. NASDAQ: PEPG investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
Myotonic Dystrophy Pipeline Analysis and Clinical Trials Assessment, 2025 by Del …
Myotonic Dystrophy Pipeline constitutes 20+ key companies continuously working towards developing 22+ Myotonic Dystrophy treatment therapies, analyzes DelveInsight.
Myotonic Dystrophy Overview:
Myotonic Dystrophy (DM) is the most prevalent form of adult-onset muscular dystrophy and falls under the category of myopathies. It exists in two primary forms: type I (DM1 or Steinert disease) and the milder type II (DM2 or proximal myotonic myopathy). Both are progressive, multisystem genetic disorders.
Symptoms vary widely, from no…
Investigation announced for Investors who lost money with shares of PepGen Inc. …
PepGen Inc is under over potential securities laws violations s in connection with certain financial statements was announced.
Investors who purchased shares of PepGen Inc. (NASDAQ: PEPG), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by PepGen Inc. regarding its business, its prospects and its operations were materially false and…
Myotonic Dystrophy Pipeline Analysis (2023) Covering Clinical Trials, Emerging T …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 20+ key pharma and biotech companies are working on 22+ pipeline drugs in the Myotonic Dystrophy therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Myotonic Dystrophy Pipeline Insight, 2023" report…
Global Peptide Drug Conjugate Clinical Trial Market 360-Degree Research with Cur …
Peptide drug conjugates (PDCs) are a novel class of therapeutics that combine the specificity and efficacy of peptides with the pharmacological properties of small molecule drugs. PDCs consist of a peptide conjugated to a small molecule drug through a linker molecule. The linker molecule is designed to be stable in the bloodstream but cleavable in the target tissue, allowing the drug to be released at the site of action. PDCs…
